Medexus Pharmaceuticals (TSE:MDP) Sets New 12-Month High – Still a Buy?

Medexus Pharmaceuticals Inc. (TSE:MDP)’s share price reached a new 52-week high on Friday . The stock traded as high as C$3.41 and last traded at C$3.28, with a volume of 19378 shares changing hands. The stock had previously closed at C$3.25.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MDP. Raymond James raised shares of Medexus Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from C$3.00 to C$4.00 in a research report on Wednesday, November 20th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Finally, Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research report on Monday, September 30th. Three research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Strong Buy” and an average price target of C$5.25.

Medexus Pharmaceuticals Trading Up 1.5 %

The firm’s 50 day simple moving average is C$2.59 and its 200-day simple moving average is C$2.41. The stock has a market capitalization of C$80.95 million, a price-to-earnings ratio of 66.00 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.